Nothing Special   »   [go: up one dir, main page]

Latest News for: eosinophilic

Edit

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Nasdaq Globe Newswire 08 Jul 2025
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis ... .
Edit

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis (Form 6-K) (Eupraxia Pharmaceuticals Inc)

Public Technologies 08 Jul 2025
The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System ("EoEHSS").
Edit

Eosinophilic Esophagitis Treatment Market Size in the 7MM was ~USD 1,800 million in the 2023, ...

GetNews 24 Jun 2025
Eosinophilic Esophagitis Current Marketed and Eosinophilic Esophagitis Emerging Therapies Eosinophilic Esophagitis Market Dynamics. Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis ...
Edit

Eosinophilic Esophagitis Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, ...

GetNews 24 Jun 2025
"Eosinophilic Esophagitis Market" ... Some of the key facts of the Eosinophilic Esophagitis Market Report ... Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies Eosinophilic Esophagitis Market Dynamics.
Edit

Eosinophilic Disorder Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, ...

GetNews 29 May 2025
"Eosinophilic Disorder Treatment Market" ... Other forms include Eosinophilic Gastroenteritis, Eosinophilic Colitis, Hypereosinophilic Syndrome (HES), and Eosinophilic Asthma, each defined by the affected organ system and severity.
Edit

Global Eosinophilic Esophagitis Market Poised for Unprecedented Growth, Projected to Skyrocket to USD 2,032.8 Billion by 2033, Reveals Future Market Insights

Pharmiweb 28 May 2025
The global eosinophilic esophagitis market is on the cusp of a remarkable transformation, according to the latest comprehensive analysis released by Future Market Insights (FMI) ... Eosinophilic ...
Edit

Eosinophilic Esophagitis Market Set to Surge as New Research Unveils Breakthrough Treatments | DelveInsight

PR Newswire 15 May 2025
Learn more about the treatment options for eosinophilic esophagitis @ Medications for Eosinophilic Esophagitis Treatment  ... To know more about the eosinophilic esophagitis treatment, visit @ Eosinophilic Esophagitis Drug Information.
Edit

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 (Form 6-K) (Eupraxia Pharmaceuticals Inc)

Public Technologies 07 May 2025
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025.
Edit

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine ...

Nasdaq Globe Newswire 05 May 2025
Eupraxia Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI ... .
Edit

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI (Form 6-K) (Eupraxia Pharmaceuticals Inc)

Public Technologies 05 May 2025
Reductions in Eosinophils. Reductions in eosinophil counts were maintained, with a mean decrease of 77% across a standard number of biopsy sites within the treated area ... PEC means the peak number of eosinophils found in esophageal biopsies.
Edit

Eosinophilic Esophagitis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Regeneron Pharmaceuticals, Sanofi, ...

GetNews 30 Apr 2025
The Key Eosinophilic Esophagitis Companies in the market include - Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr.
Edit

Eosinophilic Esophagitis Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, Prevalence, and ...

GetNews 28 Apr 2025
"Eosinophilic Esophagitis Drugs Market" ... Some of the key facts of the Eosinophilic Esophagitis Market Report ... Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies Eosinophilic Esophagitis Market Dynamics.
Edit

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

The Pilot News 22 Apr 2025
(Nippon Shinyaku), announced today that the U.S.
Edit

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis (Nippon Shinyaku Co Ltd)

Public Technologies 18 Apr 2025
Food and Drug Administration (FDA) has granted Orphan Drug Designation to NS-229 which is being developed for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
Edit

Eosinophilic oesophagitis during oral immunotherapy for peanut allergy (Swissmedic - Swiss Agency for Therapeutic Products)

Public Technologies 07 Apr 2025
) A current PV case report is a reminder to Swissmedic that eosinophilic oesophagitis is a potential adverse drug ...

Article Search

tools
×
×
×
×